Tirzepatide for High Blood Pressure
Weight loss from GLP-1 medications can reduce blood pressure. Tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP receptor agonist with 20-22% average body weight loss — the highest of any GLP-1 medication.
How Tirzepatide Helps with High Blood Pressure
Tirzepatide targets both GLP-1 and GIP receptors for enhanced appetite control and metabolic effects. This dual mechanism produces the highest weight loss of any available GLP-1 medication. For patients with high blood pressure, the significant weight loss translates to meaningful improvements in condition outcomes.
Weight loss from GLP-1 medications can reduce blood pressure. The SURMOUNT-1 clinical trial demonstrated that tirzepatide at the highest dose produces an average weight loss of 22.5% of body weight over 72 weeks.
Clinical Evidence for High Blood Pressure
High Blood Pressure affects 47% of US adults. Tirzepatide's dual receptor mechanism provides particularly strong metabolic benefits that extend beyond weight loss, including improved insulin sensitivity, better lipid profiles, and reduced inflammation.
Tirzepatide Dosing for High Blood Pressure
Tirzepatide is administered as a once-weekly subcutaneous injection. Treatment starts at 2.5mg and can increase to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerability. Each dose increase occurs at 4-week intervals.
Cost of Tirzepatide for High Blood Pressure
Compounded tirzepatide costs $199-449/month through telehealth providers. Brand-name Zepbound costs $1,100+/month without insurance. The higher cost compared to semaglutide may be justified by the greater average weight loss.